|
|
|
|
|
|
Article Detail
|
|
Label
|
|
|
Label
|
|
|
|
Cardiovascular Disease Patient Suffering with Diabetes Mellitus Type 1 and Type 2 Resistant to Treatment
|
|
| Author:
|
DR.SALAH ABD-AL KADER OMRAN
|
| Abstract:
|
Research on the suffering of chronic diabetic patients T1DM, T2DM. The body's resistance to insulin secretions. The disease has evolved over time and has complications including the retinopathy, heart disease and pressure, renal insufficiency, infections and diabetic foot, peripheral neuropathy, liver, and mental state disorders, Our work was the key or new window and the missing link to insulin resistance and the linking of diabetes to heart disease and one of the most common complications and lethal in the total death. According to the international protocols, the American Diabetes Association (FDA), the US Food and Drug Administration, academic work and technical expertise change the treatment plan and set a periodic schedule for patients after all laboratory, diagnostic, and radiological examinations are used pharmaceutical metformin From the Biguanides Group, Genomet 50/500 And we used (metformin + (DPP-IV), glitazones thiazolidinediones (TZDs) 50- 200mg Gradually from a small dose. All medications and substances that increase insulin sensitivity, metabolic syndrome are excluded by food regulation and the EC50 = method is a balance between exogenous glucose + internal glucose + insulin resistance that is the adjuvantA golden method of hand clamp infusion (Glucose clamp technique)Insulin to know and as an indicator of insulin resistance and can be converted to a number through a mathematical equation, and the immune bodies are IgA, IgM, IgG, IgE and the changes that happen T1DM, T2DM in addition to a complete blood analysis with ESR, CBC and worked within the educational and guidance program for early prediction of complications and their dimensions. Therefore the results were:
T1DM- IRS: Modify the patient's treatment plan 60%±10, The balance between food and medicine 30%±10, HbA1c 7.6%±1, fasting blood sugar 150±30, IRS±62%±10 As a clinical indication, Average value for morning reading 130±20, AlT, AST reduce 2.3%±1, Glucose control reduce HbA1c 2.9%, lipid profile reduce 4.8%, complication more common are the retina and diabetic foot 19%, hypertension 3.2%±1, body mass (BMI) reduce 26%±2. (CAD) 32%±10. Manual clamp index 7.2±2, EC50 = 60.2%±10, Unstable decline IgA, Clear increase IgM, IgG, Sensitive IgE,], [the role of tumor necrosis factor a (TNF a).
T2DM- IRS: Modify the patient's treatment plan 40%±10, The balance between food and medicine 40%±10, HbA1c 7.5%±1, fasting blood sugar 140±20, reduce IRS±52%±10 As a clinical indication, Average value for morning reading 140±20. AlT, AST reduce 2.1%±1, Glucose control reduce HbA1c 2.9%±1, lipid profile reduce 5.8%, complication more common are the retina and diabetic foot Improvement 26%±5, hypertension 3.2%±1, body mass (BMI) reduce 26%±2, (CAD) reduce 32%, Manual clamp index 5.2±2, EC50 = 70.2%±10, No real change IgA, IgM, IgG, IgE], [the role of tumor necrosis factor a (TNF a) Related In the pancreas positive or negative].
|
| Keyword:
|
Diabetes mellitus T1DM, T2DM, Insulin resistance IRS, cardiovascular disease, Glucose clamp technique, hyperlipidemia, blood pressure, infections, SystemEC50S, hyperglycemia after eating, Complication. Metabolic syndrome.
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2020.12.02.361
|
| Download:
|
Request For Article
|
|
|
|
|
|
|
|
|
|
|